calcium dobesilate monohydrate
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
67
Go to page
1
2
3
August 13, 2026
A preliminary experimental study of venoactive compounds on human lymphatic endothelial cells: cellular response and therapeutic potential.
(PubMed, Ann Surg Treat Res)
- "Human lymphatic endothelial cells (HLECs) were used to assess the effects of diosmin, calcium dobesilate, and Vitis vinifera extract...Their therapeutic effects in lymphedema may instead be mediated by microvascular stabilization through anti-inflammatory, antioxidant, and permeability-reducing mechanisms. Further experimental and clinical studies are needed to validate these findings."
Journal • Breast Cancer • Cardiovascular • Oncology • Solid Tumor
July 31, 2026
Pharmacological interventions to treat chronic venous disease: A network meta-analysis.
(PubMed, Phlebology)
- "Pentoxifylline (Relative risk [RR] = 1.69; 95% CI: 1.34 - 2.14), Micronized Purified Flavonoid Fraction (RR = 1.68; 95% CI: 1.23 - 2.29) and Sulodexide (RR = 1.61; 95% CI: 1.16 - 2.23) significantly increased ulcer healing. Calcium dobesilate (RR = 0.22; 95% CI: 0.08 - 0.63) and Centella asiatica (RR = 0.30; 95% CI: 0.11 - 0.81) significantly reduced heaviness. Red vine leaf extract (RR = 0.62; 95% CI: 0.44 - 0.87) was significantly associated with fewer adverse events.ConclusionsPharmacological interventions were efficacious for CVD treatment."
Journal • Retrospective data • Review • Cardiovascular • Pain • Venous Ulcer
May 02, 2026
Venoactive drugs in the management of chronic venous disease: A critical appraisal of the evidence and comparison with international guidelines.
(PubMed, Vascul Pharmacol)
- "The review evaluates the efficacy of various VADs, including micronized purified flavonoid fraction (MPFF), rutosides, calcium dobesilate, sulodexide, horse chestnut seed extract, and red vine leaf extract. Different medical guidelines for treating CVD from around the world recommend using VADs, though with some discrepancies on recommendation gradings. While MPFF is referred to in these guidelines as a leading option, further research is needed to better understand how different VADs can be used most effectively in treating CVD."
Journal • Review • Cardiovascular • Hypertension • Inflammation • Pain • Venous Ulcer
April 01, 2026
Effective Removal of Calcium Dobesilate Interference in Triglyceride Measurement Using Copper Oxide.
(PubMed, J Appl Lab Med)
- "CuO pretreatment effectively mitigates CD-induced negative interference in enzymatic TG assays, restoring measurement accuracy. This simple, low cost, and clinically practical approach provides a reliable solution for accurate TG monitoring in patients receiving CD therapy."
Journal
March 25, 2026
Effect of calcium dobesilate on intraretinal cysts and exudates in non-proliferative diabetic retinopathy: a Fiji ImageJ analysis.
(PubMed, BMC Ophthalmol)
- No abstract available
Journal • Diabetic Retinopathy • Retinal Disorders
March 13, 2026
Effect of calcium dobesilate on liver regeneration in rats undergoing partial hepatectomy.
(PubMed, Ulus Travma Acil Cerrahi Derg)
- "This research indicated the effects of calcium dobesilate on improving oxidative damage and liver regeneration in rats undergoing partial hepatectomy. The results of the present study showed that (preoperative-postoperative) CD improves oxidative stress and increases liver regeneration capacity after partial hepatectomy."
Journal • Preclinical
February 06, 2026
Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins
(clinicaltrials.gov)
- P4 | N=250 | Not yet recruiting | Sponsor: Oguz Arslanturk
HEOR • New P4 trial • Cardiovascular • Pain • Varicose Veins
February 04, 2026
Calcium Dobesilate Interference in Two Urinary Total Protein Detection Methods.
(PubMed, J Clin Lab Anal)
- "Calcium dobesilate did not significantly interfere with the pyrogallol red-molybdate method but did significantly interfere with the benzethonium chloride method. The direction and degree of interference were related to the urinary protein and drug concentrations. Discontinuing calcium dobesilate for 1-2 days before obtaining a urine sample for total protein detection is recommended."
Journal
January 21, 2026
The Efficacy of Calcium Dobesilate Alone or with Vascularized Lymph Node Transfer in Lymphedema Treatment: A Preliminary Study.
(PubMed, Plast Reconstr Surg)
- "In clinical practice, calcium dobesilate could be incorporated into the treatment protocol to enhance the efficacy of vascularized lymph node transfer in lymphedema."
Journal • Fibrosis • Immunology • Inflammation
January 12, 2026
Diverse and Atypical Presentations of Acroangiodermatitis of Mali: Diagnostic Insights From Three Cases.
(PubMed, Cureus)
- "The patients were started on oral calcium dobesilate and topical corticosteroids and were referred for vascular surgical evaluation. This case series highlights the importance of recognizing the diverse and atypical presentations of acroangiodermatitis of Mali, emphasizing that biopsy and dermoscopy are critical for a definitive diagnosis."
Journal • Cardiovascular • Dermatitis • Dermatology • Hypertension • Immunology • Kaposi Sarcoma • Oncology • Sarcoma • Solid Tumor • Varicose Veins
October 31, 2025
Optimization of Microcirculation Disorder in Non-proliferative Diabetic Retinopathy by Combination of Traditional Chinese and Western Medicine: Analysis of the Efficacy Difference between Tongluo Mingmu and Danshen Preparation Combined with Calcium Dobesilate
(ChiCTR)
- P=N/A | N=60 | Recruiting | Sponsor: First Hospital of Northwest University; First Hospital of Northwest University
New trial • Diabetic Retinopathy • Retinal Disorders
September 04, 2025
Pharmacokinetics of orally administered calcium dobesilate in Warmblood horses.
(PubMed, Schweiz Arch Tierheilkd)
- "Only plasma samples were analysed and calcium dobesilat was only measured after the treatment period of seven days. Calcium dobesilate was absorbed by the equine gastrointestinal system and reached detectable plasma concentrations."
Journal • PK/PD data • Hematological Disorders • Immunology
June 10, 2025
Effect of calcium dobesilate on macular microvasculature in patients with diabetic retinopathy.
(PubMed, PLoS One)
- "The administration of CaD positively influences macular microcirculation in DR patients, demonstrating its effectiveness even in advanced stages of the disease."
Journal • Retrospective data • Diabetic Retinopathy • Retinal Disorders
June 04, 2025
Longitudinal changes in each retinal layer thickness in patients with moderate or more severe diabetic retinopathy taking calcium dobesilate.
(PubMed, PLoS One)
- "In patients with moderate or more severe DR, the group taking CaD did not show significant reductions in GCC and INL thicknesses over time compared with the group not taking CaD. These findings suggest that CaD could have a protective effect on the inner retina, even in those with more advanced stages than mild DR."
Journal • Retrospective data • Diabetic Retinopathy • Retinal Disorders
May 23, 2025
Clinical evidence of venoactive drugs in diabetic microvascular complications: a scoping review.
(PubMed, Int Angiol)
- "Calcium dobesilate (CaD), was the most assessed VAD in DR (85%), DN (86%), and DPN (50%)...Our findings suggest that VADs, in particular CaD, may represent a promising therapeutic option for the treatment of patients with both CVD and DmVC. Medical recommendations for VADs prescription should consider patients' microvascular status, evidence about VADs, as well as the multi-modal treatment approach."
Journal • Diabetic Nephropathy • Diabetic Neuropathy • Diabetic Retinopathy • Nephrology • Pain • Renal Disease • Retinal Disorders
May 19, 2025
Acupuncture and related therapies for diabetic retinopathy: A systematic review and network meta-analysis.
(PubMed, Medicine (Baltimore))
- "EA combined with AC combined with TCM may be the most effective treatment for DR. AC and the related treatments have significant efficacy in treating DR, improving vision, and reducing macular edema with relatively few adverse effects. The use of integrative therapies combining AC and its related therapies can be promoted."
Clinical • Journal • Retrospective data • Review • Diabetes • Diabetic Retinopathy • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders
May 17, 2025
Combining ranibizumab with calcium dobesilate to reduce injection frequency in diabetic macular edema treatment.
(PubMed, Int Ophthalmol)
- "Combination therapy with calcium dobesilate and ranibizumab decreased the frequency of intravitreal injections and led to greater improvements in BCVA and CMT compared to ranibizumab alone over 12 months. Both treatments were well-tolerated, with the combination therapy demonstrating a favorable safety profile."
Clinical • Journal • Diabetic Macular Edema • Ophthalmology
May 15, 2025
Efficacy and Safety of Qiming Granule for Nerve Injury Associated with Non-proliferative Diabetic Retinopathy: A Multicenter, Randomized, Non-inferiority, Active-Controlled Clinical Trial.
(PubMed, Chin J Integr Med)
- "Qiming Granule demonstrates non-inferiority in terms of efficacy and safety as an early treatment for nerve injury associated with NPDR. (Registration No. ISRCTN39825773)."
Clinical • Head-to-Head • Journal • Diabetic Retinopathy • Retinal Disorders
May 11, 2025
"The Role of Venoactive Compounds in the Treatment of Chronic Venous Disease".
(PubMed, J Vasc Surg Venous Lymphat Disord)
- "The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and non-interventional approaches like compression, to optimize patient outcomes and improve quality of life."
Journal • Review • Inflammation • Pain • Venous Ulcer
February 18, 2025
Minimizing serum creatinine interference in automated laboratory analyses through the implementation of urea/creatinine ratio alerting mechanisms.
(PubMed, Clin Chim Acta)
- "The implementation of an automated UCR-based screening protocol has been shown to efficiently pinpoint samples with drug-related interference. This strategic approach not only decreases clinical risk but also guarantees the fidelity of serum Cr measurements without undermining the overall productivity of the laboratory's automated workflow."
Journal
January 21, 2025
Fasting/postprandial, single oral, randomized, open, two-formulation, two-cycle, cross-over bioequivalence study of calcium dobesilate capsules in healthy subjects
(ChiCTR)
- P=N/A | N=52 | Completed | Sponsor: Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University; Affiliated Hospital of Traditional Chinese Medicine of Southwest
New trial • Cardiovascular
January 08, 2025
Efficacy of Calcium Dobesilate Versus Tranexamic Acid for Treating Heavy Menstrual Bleeding
(clinicaltrials.gov)
- P=N/A | N=100 | Not yet recruiting | Sponsor: University of Health Sciences Lahore
New trial • Gynecology • Women's Health
November 27, 2024
TXA: Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin
(clinicaltrials.gov)
- P2/3 | N=100 | Completed | Sponsor: District Headquarters Teaching Hospital Sahiwal
New P2/3 trial • Agranulocytosis • Granulocytopenia • Immunology
October 11, 2024
Discovery of a potent, Kv7.3-selective potassium channel opener from a Polynesian traditional botanical anticonvulsant.
(PubMed, Commun Chem)
- "GA is, uniquely to our knowledge, 100% selective for Kv7.3 versus other Kv7 homomers; it requires S5 residue Kv7.3-W265 for Kv7.2/3 activation, and it ameliorates pentylenetetrazole-induced seizures in mice. Structure-activity studies revealed that the FDA-approved vasoprotective drug calcium dobesilate, a GA analog, is a previously unrecognized Kv7.2/3 channel opener. Also an active aspirin metabolite, GA provides a molecular rationale for the use of T. populnea as an anticonvulsant in Polynesian indigenous medicine and presents novel pharmacological prospects for potent, isoform-selective, therapeutic Kv7 channel activation."
Journal • CNS Disorders • Epilepsy
September 21, 2024
Which dose of calcium dobesilate is more effective and safe in chronic venous insufficiency? Multicenter retrospective clinical trial.
(PubMed, Phlebology)
- "Higher doses of calcium dobesilate markedly enhance the management of CVI symptoms and reduce edema more effectively than lower doses, particularly in patients with advanced CVI. These findings support the use of higher dosages for optimal treatment, though further research is needed to fully evaluate long-term safety."
Journal • Retrospective data • Cardiovascular
1 to 25
Of
67
Go to page
1
2
3